
|Videos|April 15, 2021
Case-Based Peer Perspectives: 57-Year-Old Man With ALK+ Non–Small Cell Lung Cancer
Author(s)Joshua M. Bauml, MD
Joshua M. Bauml, MD, provides insight on the treatment of ALK fusion+ non-small cell lung cancer with tyrosine kinase inhibitors.
















